Primary Care Hypertension Guidelines: What’s New for Primary Care

Auteurs-es

  • Gregory L. Hundemer
  • Kristin A. Terenzi
  • Rémi Goupil

Résumé

Hypertension remains the leading modifiable risk factor for cardiovascular disease and mortality, yet recent data demonstrate declining rates of hypertension treatment and control in Canada. Because most hypertension care occurs in primary care, improving population-level outcomes requires guidance that is pragmatic, streamlined, and easily implemented into routine primary care practice. To address this need, Hypertension Canada has released a new Primary Care Hypertension Guideline, developed as part one of a two-part guideline strategy and informed by contemporary evidence and extensive input from primary care providers and patients. This article highlights the most clinically relevant updates from the 2025 Hypertension Canada Primary Care Guideline for front-line clinicians. Major changes include adoption of a lower blood pressure threshold (≥130/80 mmHg) to define hypertension, selective initiation of pharmacotherapy based on blood pressure level and cardiovascular risk, and a simplified target of systolic blood pressure <130 mmHg for most patients when tolerated. The guideline emphasizes accurate blood pressure measurement, routine use of out-of-office monitoring, and foundational lifestyle modification for all individuals with hypertension. Importantly, for patients requiring medication, early initiation of low-dose single-pill combination therapy is recommended to improve blood pressure control and reduce therapeutic inertia. These recommendations are embedded within the World Health Organization’s HEARTS framework, providing standardized diagnostic and treatment algorithms tailored to Canadian primary care. Together, these updates are intended to simplify hypertension management, enhance guideline uptake, and improve cardiovascular outcomes at the population level.

Biographies de l'auteur-e

Gregory L. Hundemer

Dr. Greg Hundemer is a hypertension specialist and staff nephrologist at the Ottawa Hospital, an Associate Professor of Medicine at the University of Ottawa, and a Scientist at the Ottawa Hospital Research Institute. His clinical and research interests focus on the role of aldosterone in hypertension and vascular disease. His research has been supported by the NIH, CIHR, and Kidney Foundation of Canada. He holds the Lorna Jocelyn Wood Chair for Kidney Research at the University of Ottawa and serves as Co-Chair of the Hypertension Canada Clinical Practice Guidelines Committee.

Kristin A. Terenzi

Dr. Kristin Terenzi is a family physician in private practice in Woodbridge, Ontario, and a Fellow in the College of Family Physicians. She was a member of the guideline committee that developed the 2025 Hypertension Canada Guideline for the Diagnosis and Treatment of Hypertension in Adults in Primary Care.

Rémi Goupil

Dr. Rémi Goupil is a hypertension specialist and nephrologist at the Hôpital du Sacré-Coeur de Montréal, Associate Professor at the Université de Montréal and a Junior 2 clinician-scientist of the Fonds de recherche du Québec‑Santé. His research is focused on optimising blood pressure measurements and hypertension care in various populations. His work has received multiple funding by the CIHR, the Kidney Foundation and the Heart and Stroke Foundation. Since 2024, he serves as Co-Chair for the Hypertension Canada Clinical Practice Guidelines Committee and is the president-elect of the Société québécoise d’hypertension artérielle.

Références

Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389(14):1273-1285. doi:10.1056/NEJMoa2206916

Global Cardiovascular Risk Consortium; Magnussen C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, Aviles-Santa L, et al. Global effect of cardiovascular risk factors on lifetime estimates. N Engl J Med. 2025;393(2):125-138. doi:10.1056/NEJMoa2415879

Garies S, Hao S, McBrien K, Williamson T, Peng M, Khan NA, et al. Prevalence of hypertension, treatment, and blood pressure targets in Canada associated With the 2017 American College of Cardiology and American Heart Association Blood Pressure Guidelines. JAMA Netw Open. 2019;2(3):e190406. doi:10.1001/jamanetworkopen.2019.0406

World Health Organization Team. Global report on hypertension: the race against a silent killer [Internet]. Geneva: World Health Organization; 2023 [cited 2026 Mar 3]. Available from: https://www.who.int/publications/i/item/9789240081062

Leung AA, Williams JVA, McAlister FA, Campbell NRC, Padwal RS; Hypertension Canada’s Research and Evaluation Committee. Worsening hypertension awareness, treatment, and control rates in Canadian women between 2007 and 2017. Can J Cardiol. 2020;36(5):732-739. doi:10.1016/j.cjca.2020.02.092

Leung AA, Williams JVA, Padwal RS, McAlister FA. Prevalence, patient awareness, treatment, and control of hypertension in Canadian adults with common comorbidities. CJC Open. 2024;6(9):1099-1107. doi:10.1016/j.cjco.2024.05.012

Goupil R, Tsuyuki RT, Terenzi KA, Santesso N, Hundemer GL. Ushering in a new era of Hypertension Canada Guidelines: a roadmap of what lies ahead. Can J Cardiol. 2025;41(1):159-162. doi:10.1016/j.cjca.2024.10.020

Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197(20):E549-E564. doi:10.1503/cmaj.241770

World Health Organization Team. HEARTS technical package for cardiovascular disease management in primary health care: risk based CVD management. Geneva: World Health Organization; 2020 [cited 2026 Mar 3]. Available from: https://www.who.int/publications/i/item/9789240001367

Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310(7):699-705. doi:10.1001/jama.2013.108769

Jaffe MG, Young JD. The Kaiser Permanente Northern California Story: improving hypertension control from 44% to 90% in 13 years (2000 to 2013). J Clin Hypertens (Greenwich). 2016;18(4):260-261. doi:10.1111/jch.12803

Campbell NRC, Ordunez P, Giraldo G, Rodriguez Morales YA, Lombardi C, Khan T, et al. WHO HEARTS: a global program to reduce cardiovascular disease burden: experience implementing in the Americas and opportunities in Canada. Can J Cardiol. 2021;37(5):744-755. doi:10.1016/j.cjca.2020.12.004

Guo X, Zhang X, Guo L, Li Z, Zheng L, Yu S, et al. Association between pre-hypertension and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Curr Hypertens Rep. 2013;15(6):703-716. doi:10.1007/s11906-013-0403-y

Whelton PK, O’Connell S, Mills KT, He J. Optimal antihypertensive systolic blood pressure: a systematic review and meta-analysis. Hypertension. 2024;81(11):2329-2339. doi:10.1161/HYPERTENSIONAHA.124.23597

Franklin SS, Thijs L, Hansen TW, O’Brien E, Staessen JA. White-coat hypertension: new insights from recent studies. Hypertension. 2013;62(6):982-987. doi:10.1161/HYPERTENSIONAHA.113.01275

Thakkar HV, Pope A, Anpalahan M. Masked hypertension: a systematic review. Heart Lung Circ. 2020;29(1):102-111. doi:10.1016/j.hlc.2019.08.006

SPRINT Research Group; Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, et al. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384(20):1921-1930. doi: 10.1056/NEJMoa1901281

Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126(17):2105-2114. doi:10.1161/CIRCULATIONAHA.112.096156

Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77(2):692-705. doi:10.1161/HYPERTENSIONAHA.120.15781

Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;72(4):846-853. doi:10.1161/HYPERTENSIONAHA.118.11308

Téléchargements

Publié

2026-07-28

Comment citer

1.
Primary Care Hypertension Guidelines: What’s New for Primary Care. Can Prim Care Today [Internet]. 28 juill. 2026 [cité 29 juill. 2026];4(1):5–12. Disponible à: https://canadianprimarycaretoday.com/article/view/4-1-Hundemer_et_al

Numéro

Rubrique

Articles

Comment citer

1.
Primary Care Hypertension Guidelines: What’s New for Primary Care. Can Prim Care Today [Internet]. 28 juill. 2026 [cité 29 juill. 2026];4(1):5–12. Disponible à: https://canadianprimarycaretoday.com/article/view/4-1-Hundemer_et_al